Skip to main content
Home
FULL MENU Close Menu
Home
Home

Jennifer Smith

Jennifer Smith is the editor of Oncology Practice, part of MDedge Hematology/Oncology. She was previously the editor of Hematology Times, an editor at Principal Investigators Association, and a reporter at The Oneida Daily Dispatch. She has a BS in journalism.

News

Umbralisib gains FDA breakthrough designation for MZL

Author:
Jennifer Smith
Publish date: January 25, 2019

Umbralisib is a PI3K-delta inhibitor being developed for the treatment of adults with marginal zone lymphoma.

  • Read More

News

Combo treatment may improve quality of life in CTCL

Author:
Jennifer Smith
Publish date: January 24, 2019

LA JOLLA, CALIF. – In a small study, patients experienced relief from pruritus after just one cycle of treatment with brentuximab vedotin plus...

  • Read More

News

Are single agents better than chemo for relapsed/refractory PTCL?

Author:
Jennifer Smith
Publish date: January 24, 2019

LA JOLLA, CALIF. – Complete response rates and survival times were better among patients who received single-agent therapy.

  • Read More

Video

Four-drug combo shows durable responses in relapsed/refractory lymphomas

Author:
Jennifer Smith
Publish date: January 19, 2019

LA JOLLA, CALIF. – The phase 1 study tested the addition of a histone deacetylase inhibitor to platinum-based chemotherapy.

  • Read More

News

FDA approves third trastuzumab biosimilar

Author:
Jennifer Smith
Publish date: January 18, 2019

The drug is approved for treatment of HER2-overexpressing breast cancer and HER2-overexpressing metastatic gastric or gastroesophageal junction...

  • Read More

News

Long-term mogamulizumab appears safe, effective in CTCL

Author:
Jennifer Smith
Publish date: January 18, 2019

LA JOLLA, CALIF. – Investigators said that prolonged treatment with the drug does not appear to pose an increased safety risk.

  • Read More

News

Zanubrutinib receives breakthrough designation for MCL

Author:
Jennifer Smith
Publish date: January 18, 2019

The Bruton’s tyrosine kinase inhibitor was evaluated in a phase 2 trial.

  • Read More

News

Chidamide may be more effective in PTCL than previously thought

Author:
Jennifer Smith
Publish date: January 16, 2019

LA JOLLA, CALIF. – Chidamide produced a higher response rate in relapsed/refractory PTCL patients than what was observed in a prior phase 2 trial...

  • Read More

Video

Epigenetics is a hot topic at TCLF 2019

Author:
Jennifer Smith
Publish date: January 15, 2019

LA JOLLA, CALIF. – New developments include using epigenetic therapy to enhance immune checkpoint therapy and using epigenetic-based combination...

  • Read More

News

Registry data favor CHOEP regimen for PTCL

Author:
Jennifer Smith
Publish date: January 15, 2019

LA JOLLA, CALIF. – Registry data have influenced the treatment of patients with PTCL in the Czech Republic.

  • Read More

News

FDA approves new ALL treatment for children, young adults

Author:
Jennifer Smith
Publish date: January 7, 2019

The asparagine-specific enzyme is approved as part of a multiagent chemotherapy regimen.

  • Read More

News

FDA expands dasatinib indication to children with Ph+ ALL

Author:
Jennifer Smith
Publish date: January 3, 2019

The FDA approved dasatinib in combination with chemotherapy for children with newly diagnosed disease.

  • Read More

News

Checkmate 436: Two-drug combo is ‘promising’ for PMBCL

Author:
Jennifer Smith
Publish date: December 21, 2018

SAN DIEGO – The early results suggest a high overall response to the drug combination.

  • Read More

News

ECHELON-2: BV-CHP boosts survival in PTCL

Author:
Jennifer Smith
Publish date: December 20, 2018

SAN DIEGO – The newly approved regimen outperformed the standard CHOP regimen in this rare cancer.

  • Read More

News

Phase 3 data support apixaban for cancer-associated VTE

Author:
Jennifer Smith
Publish date: December 13, 2018

The rate of major bleeding was similar with apixaban and dalteparin.

  • Read More

Pages

  • « first
  • …
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • last »

Privacy Policy

Do Not Sell My Personal Information

Terms of Use

Editorial Policy

Cookie Policy

Ad Policy

Medscape Customer Support

Frequently Asked Questions

 

Advertise with MDedge

See more with MDedge! See our Other Publications

MDedge: Keeping You Informed. Saving You Time.

Copyright  © 2021 Frontline Medical Communications Inc., Parsippany, NJ, USA. All rights reserved. Unauthorized use prohibited. The information provided is for educational purposes only. Use of this Web site is subject to the medical disclaimer.

Close